Arrowhead Pharmaceuticals Receives European Commission Marketing Authorization For REDEMPLO To Lower Triglyceride Levels In Adult Patients With Familial Chylomicronemia Syndrome

뉴스 본문을 불러오고 있어요.

Arrowhead Pharmaceuticals Receives European Commission Marketing Authorization For REDEMPLO To Lower Triglyceride Levels In Adult Patients With Familial Chylomicronemia Syndrome | 웨이프 WAPE

Arrowhead Pharmaceuticals Receives European Commission Marketing Authorization For REDEMPLO To Lower Triglyceride Levels In Adult Patients With Familial Chylomicronemia Syndrome

기사 요약

관련 종목

댓글 —